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A B S T R A C T
Introduction. Numerous testosterone (T) formulations are available, each with differing effects on serum parameters.
Aim. The aim of this study was to compare the long-term effects of topical, injectable, and implantable pellet T
formulations in hypogonadal men.
Methods. Retrospective review of hypogonadal men treated with a single T formulation was performed: 47 men on T
gels, 57 on injectable T, and 74 on T pellets were identiﬁed. Total T (TT), calculated free T (FT), estradiol (E),
hemoglobin (Hgb), hematocrit (Hct), prostate-speciﬁc antigen (PSA), total cholesterol (Tchol), triglycerides (TG),
low-density lipoprotein (LDL), andhigh-density lipoprotein (HDL) cholesterolwere evaluated at baseline and every 3–6
months for 3 years. Serum parameters were compared using a mixed model linear regression for repeated measures.
Main Outcome Measures. Effects of topical, injectable, and pellet T formulations on serum hormone levels, Hgb,
Hct, lipid parameters and PSA.
Results. Men in the injectableTgroupwere younger (42.5 ± 12.3 years) than in the gel (54.1 ± 9.8 years) or pellet groups
(53.8 ± 13.0 years), and baseline FT, Hgb, and Hct were higher in the injectable T group than in gel or pellet groups.
Increases inTTandFTwereobserved throughout follow-up in all groups. Increases inEwereobserved at in allTgroups
and throughout follow-up in injectable andgel groups.NoPSA increaseswereobserved.Erythrocytosis (Hct > 50%)was
more common with injectable T (66.7%) than with T gels (12.8%) or pellets (35.1%, P < 0.0001). Transient changes in
cholesterol, TG, and LDL were observed, and no signiﬁcant changes were seen in HDL for any group.
Conclusions. All T formulations increase serum T and FT. More signiﬁcant increases in E occur with injectable T
and T gels. Changes in Hgb and Hct are most signiﬁcant with injectable T, and effects on lipids are variable and
inconsistent. Selection of T formulations must account for individual patient preferences and the effects of each
formulation. Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, and Lipshultz LI. Comparison of the
effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-
specific antigen. Sex Med 2015;3:165–173.
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Introduction
Hypogonadism affects approximately 2–4million men in the United States, and is
characterized by low serum testosterone (T) levels
in association with signs and symptoms of
hypogonadism including fatigue, decreased libido,
erectile dysfunction, depression, anemia, and
decreased muscle mass and bone density [1,2]. In
addition to ameliorating hypogonadal symptoms
[1,3], T therapy (TTh) can lead to increased
muscle mass and bone density [4–6], and reversal
of the metabolic syndrome [2,7]. However, TTh is
associated with potential adverse effects including
elevated serum estrogen levels, gynecomastia,
local reactions, alterations in serum lipids,
erythrocytosis, testicular atrophy, male infertility,
and cardiovascular effects [1,2,8–11].
Numerous T formulations are Food and Drug
Administration approved in the United States for
the treatment of hypogonadism. Several commonly
used T formulations include injectables, transder-
mal gels, and implantable pellets [12]. While all
T preparations are effective, the likelihood of
associated side effects is determined by dosage,
pharmacokinetics, and method of administration
[12,13]. As such, the selection of T preparation
should be a joint decision between the patient and
physician, and includes consideration of treatment
efﬁcacy, cost, acceptability of the therapy by the
patients, and likelihood of speciﬁc adverse effects
[2,12].However, a relative dearth of long-term data
directly comparing the effects of T formulations in
men on TTh limits physicians’ ability to counsel
their patients. To better understand how various T
formulations impact not only serum T levels, but
also the likelihood of related adverse effects, we
retrospectively compared the long-term effects of
injectable, transdermal, and subcutaneous T pellet
formulations in hypogonadal men.
Aims
We sought to compare the long-term effects of
topical, injectable, and implantable pellet T formu-
lations in hypogonadal men on serum hormone,
hemoglobin (Hgb), hematocrit (Hct), lipid, and
prostate-speciﬁc antigen (PSA) levels.Our goal was
to assess the unique and common effects of each T
formulation in order to better inform selection ofT
formulations for individual patients. We hypoth-
esized that different T formulations would have
varying effects on both serum hormone parameters
as well as the likelihood of adverse events.
Methods
Patient Identification and Data Acquisition
After approval by the Institutional Review Board of
BaylorCollege ofMedicine, retrospective reviewof
hypogonadal men treated with a single T formula-
tion between 2007 and 2012 was performed. Only
men that were T naïve or those who had been off of
T for 3 or more months prior to restarting TTh
were included in the analysis. Men were diagnosed
with hypogonadism using both clinical symptoms
of hypogonadism, including erectile dysfunction,
decreased libido, and/or decreased energy, as well
as evidence of low serum T (≤350 ng/dL). All
included men were diagnosed with secondary
hypogonadism. We identiﬁed 47 men treated with
T gels, 57 with injectable T, and 74 with subcuta-
neousTpellets thatmet our inclusion criteria.Men
using T gels applied drug daily based on manufac-
turer’s recommendations (Testim® 50–100 mg T
[one to two packets applied to the shoulder area
daily; Endo, Ballsbridge, Ireland], Androgel®
1.62% 20.25–80.1 mg T [two to four pumps
applied to the skin daily; AbbVie, North Chicago,
IL, USA]), and men on T pellets (75 mg crystalline
T/pellet) were implanted with 10–14 pellets to
achieve a peak serum T level of 500–800 ng/dL
every 3–6 months [14]. Men on injectable T for-
mulations injected 100–200 mg of T cypionate or
enanthate intramuscularly weekly. If men devel-
oped serum estradiol (E) levels >5 pg/mL, the
upper limit of our lab’s reference range, they were
treated with oral aromatase inhibitor (AI).
Patient demographics, total T, free T (FT), E,
Hgb, Hct, PSA, total cholesterol (Tchol),
triglycerides (TG), low-density lipoprotein (LDL),
and high-density lipoprotein (HDL) were evalu-
ated at baseline and every 3–6 months for 3 years.
All samples were analyzed in the Laboratory for
Male Reproductive Research and Testing at Baylor
College of Medicine on a single Beckman Coulter
Access2 assay system (Beckman Coulter, Brea, CA,
USA). Hormone levels were determined using
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enzyme-linked immunoassay. As the deﬁnition for
erythrocytosis in the literature ranges from
50–54%, we deﬁned erythrocytosis as Hct ≥50%,
which we use in clinical practice to identify patients
requiring therapeutic phlebotomy or T dose
adjustment.
Statistical Analysis
Baseline and follow-up serum values were com-
paredwithin each group using amixedmodel linear
regression for repeated measures. Erythrocytosis
rates were determined and compared between
groups, and the time to development of
erythrocytosis in each group was determined by
averaging the time it took for subjects to develop
Hct ≥50%. All analyses were performed using the
Statistical Package for the Social Sciences (SPSS)
for Mac Version 22 (IBM Corporation, Armonk,
NY, USA) with P < 0.05 considered statistically
signiﬁcant.
Main Outcome Measures
Theprimary outcomes of this studywere the effects
of T topical, injectable, and pellet formulations
on serum hormone levels. Secondary outcomes
included the effects of the above T formulations on
Hgb, Hct, lipid parameters, and PSA levels.
Results
At baseline, men in the injectable T group were
younger (42.5 ± 12.3 years) than in the T gel or T
pellet groups (54.1 ± 9.8 and 53.8 ± 13.0 years,
respectively, P < 0.001) (Table 1). More men in the
T pellet group had hypertension and hyper-
lipidemia at baseline, and more men in the T gel
group had erectile dysfunction. Baseline FT, Hgb
and Hct were slightly higher in the injectable T
group than in theTgel orTpellet groups (Table 2).
No signiﬁcant differences were observed in other
serum parameters at baseline. Increases in mean T
and FT levels were observed beginning at 3months
after TTh initiation and persisted throughout 3
years of follow-up in all T formulation groups
(Figure 1, Supplementary Table S1). Overall, TT
and FT levels were signiﬁcantly higher in men
receiving injectable T than in T gel or pellet
groups.
Signiﬁcant increases in E were observed in the
injectable T group beginning at 3 months and
persisted throughout the follow-up period. E
Table 1 Cohort demographics
T gels Injectable T T pellets
P valuen = 47 n = 57 n = 74
Characteristics (mean [SD])
Age at start of rx (years) 54.1 (9.8) 42.5 (12.3) 53.8 (13.0) 0.001
Follow-up (months) 26.2 (10.6) 29.8 (8.8) 28.2 (8.6) 0.145
Range of follow-up (months) 2.7–55.8 7.1–41.1 4.3–41.0
T naïve men 41 (87.2) 36 (63.2) 33 (44.6)
Men off T for ≥3 months 6 (12.8) 21 (36.8) 41 (55.4)
Comorbidities (n[%])
Diabetes mellitus 3 (6.4) 5 (8.8) 11 (14.9) 0.288
Hypertension 6 (12.8) 3 (5.3) 18 (24.3) 0.009
Hyperlipidemia 5 (10.6) 5 (8.8) 25 (33.8) 0.003
Prostate cancer 6 (12.8) 4 (7.0) 8 (10.8) 0.609
Erectile dysfunction 32 (68.1) 19 (33.3) 37 (50) 0.002
rx = treatment; SD = standard deviation; T = testosterone.
Table 2 Baseline serum values
Baseline hormones T gels mean (SD) Injectable T mean (SD) T pellets mean (SD) P value
Total testosterone (ng/dL) 300 (89.6) 306 (164.0) 268 (167.4) 0.297
Free testosterone (ng/dL) 5.9 (1.6) 7.5 (5.0) 5.7 (3.8) 0.033
Estradiol (pg/mL) 2.66 (0.96) 2.71 (1.36) 2.80 (1.77) 0.876
PSA (ng/mL) 0.879 (0.72) 0.725 (0.53) 1.237 (1.48) 0.096
Hemoglobin (g/dL) 15.1 (1.1) 15.6 (1.3) 14.9 (1.2) 0.008
Hematocrit (%) 44.6 (3.1) 46.0 (3.7) 44.3 (3.3) 0.024
Total cholesterol (mg/dL) 191 (45.1) 180 (40.1) 189 (40.2) 0.404
Triglycerides (mg/dL) 206 (205.4) 180 (116.9) 205 (215.2) 0.743
LDL cholesterol (mg/dL) 106 (35.4) 100 (37.5) 106 (33.2) 0.655
HDL cholesterol (mg/dL) 47 (11.1) 43 (12.1) 47 (11.6) 0.16
HDL = high-density lipoprotein; LDL = low-density lipoprotein; PSA = prostate-specific antigen; SD = standard deviation; T = testosterone.
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levels were also consistently increased from base-
line in the T gel group throughout follow-up, as
well as after 3–6 months of follow-up with T
pellets (Figure 2). Men with E levels >5 pg/mL
were treated with AIs, with 1, 12, and 22 men in
the T gel, injectable T, and T pellet groups requir-
ing therapy. A sensitivity analysis excluding
AI-treated men did not signiﬁcantly affect E levels
during follow-up in any group (data not shown). E
levels in AI-treated men normalized in all patients.
Figure 1 Changes in serum testoster-
one (T) and free testosterone (FT)
levels during testosterone therapy
(TTh). Changes in (A) serum total T,
and (B) serum FT were assessed as a
function of time and T formulation.
*P < 0.05, **P < 0.001.
Figure 2 Changes in serum estradiol
(E levels during testosterone therapy
(TTh). Changes in serum estradiol
were assessed as a function of time
and testosterone (T) formulation.
*P < 0.05, **P < 0.001.
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Multivariate analysis demonstrated that only T
level (P = 0.01), and not age (P = 0.126) or body
mass index (BMI) (P = 0.813), affected E levels in
all T formulation groups, with higher E levels in
subjects with higher T levels.
A signiﬁcant concern in men on TTh is that
exogenous T will increase the risk of developing
prostate cancer (CaP) or its progression. We
evaluated the risk of CaP incidence or progression
as a function of T formulation. There were 18 men
in our cohort with a prior history of CaP, and all
had been treated with either radical prostatectomy
or radiation therapy; no men were on active sur-
veillance. No signiﬁcant PSA increases were
observed in any T formulation group, regardless of
whether patients had a history of CaP (Table 3).
Only one subject in the T pellet group had a new
diagnosis of CaP during the study, and was diag-
nosed with Gleason 3 + 4 CaP 2 years after TTh
initiation. There were no CaP recurrences in any
of the subjects with a history of CaP during the
follow-up period.
Erythrocytosis is a common adverse effect of
TTh, with variable incidence as a function of T
formulation. Signiﬁcant increases in Hgb were
observed by 6 months after TTh initiation in the
injectable T and T gel groups, and by 9 months
after TTh initiation in the T pellet group
(Figure 3). At 9 months, when Hgb plateaus in all
groups, the mean ± SD increase in Hgb was
1.06 ± 1.40 g/dL in the injectable T group, and
this increase was comparable with the mean
increase in the T gel and pellet groups 0.79 ± 0.94
and 0.81 ± 1.15 g/dL, respectively, (P = 0.598,
Table 4). Similarly, signiﬁcant increases in Hct
were observed by 3 months after TTh initiation in
the T pellet groups and by 6 months in the inject-
able T and T gel groups (Figure 3). These
increases in Hgb and Hct persisted throughout
follow-up. However, the rate of erythrocytosis,
deﬁned as Hct ≥50% in our study, was more
common in the injectable T group (66.7%) than in
the T gel (12.8%) and T pellet (35.1%) groups
(P < 0.0001) (Table 5). Erythrocytosis occurred
signiﬁcantly earlier in the injectable T group
(10.5 ± 9.1 months) when compared with the T gel
(14.0 ± 12.6 months) and T pellet (16.4 ± 10.7
months) groups (P = 0.01).
Exogenous T is known to variably affect lipid
proﬁles, although no consistent effects have been
determined as a function of T formulation. In our
cohort, we observed transient decreases in mean
Tchol in the T gel group at 9 and 36 months, and
the T pellet group at 3, 18, and 24 months
(Supplementary Figure S1). The T pellet group
also demonstrated a transient decrease in TG at 36
months, and in LDL at 3 and 18 months, respec-
tively. No signiﬁcant changes were observed in
HDL for any T formulation group.
Discussion
Serum T levels decline at a rate of 0.4–2.6% per
year as men age, resulting in hypogonadal levels in
approximately 20% of men over 60, 30% of
men over 70, and 50% of men over 80 [15–17].
The improved recognition of the sequelae of
hypogonadism coupled with an aging male popu-
lation has led to a signiﬁcant rise in the treatment
of androgen deﬁciency [18]. A recent study found
that 3.8% of men 60 years or older were pre-
scribed T, and the use of T has increased by over
170% between 2007 and 2013 [2,19,20]. Given its
widespread use, it is essential to understand the
long-term beneﬁts and adverse effects of TTh.
Furthermore, because multiple TTh options are
available, understanding the effect proﬁle of each
is useful when selecting T formulations for indi-
vidual patients. In this study, we evaluated the
long-term effects of injectable, gel, and pellet T
formulations to determine the impact on serum
hormones and the rates of common adverse effects
of each T formulation.
As expected, all T formulations resulted in
increases in serum T and FT levels, which were
sustained throughout 3 years of therapy. All forms
of TTh resulted in a signiﬁcant increase in E
levels, although this increase was present through-
out follow-up in men treated with injectable T and
T gels, yet lasted only up to the 6-month
follow-up point in men using T pellets. These
ﬁndings are supported by prior work observing an
Table 3 Changes in PSA by T formulation and CaP
status
T formulation
Baseline PSA
(ng/mL)
Final follow-Up
PSA (ng/mL) P
valueMean (SD) Mean (SD)
Gels (n = 47) 0.90 (0.72) 1.02 (0.83) 0.52
With CaP (n = 6) 0.06 (0.12) 0.01(0.001) 0.51
Without CaP (n = 41) 1.05 (0.67) 1.23 (0.76) 0.43
Injectables (n = 57) 0.73 (0.53) 0.73 (0.47) 0.99
With CaP (n = 4) 0.01 (0.00) 0.01 (0.00) 1.00
Without CaP (n = 53) 0.78 (0.51) 0.86 (0.39) 0.55
Pellets (n = 74) 1.24 (1.48) 1.41 (1.31) 0.54
With CaP (n = 8) 0.65 (1.45) 0.04 (0.05) 0.81
Without CaP (n = 66) 1.31 (1.48) 1.46 (1.28) 0.60
CaP = protstate cancer; PSA = prostate-specific antigen; SD = standard
deviation; T = testosterone.
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increase in E during TTh using injectable and gel
T formulations [20]. The increase in E results
from peripheral aromatization of T in adipose
tissue and is typically more prevalent in older men
on TTh, in part because of higher fat mass in older
men [21]. In our study, there was no correlation
between age and/or BMI and E levels, and the only
variable impacting E level on multivariate analysis
was T level, suggesting that higher T levels drive
aromatization in our cohort. This is further sup-
ported by the decrease in E levels after initiation of
AI therapy in men with elevated E levels. In our
cohort 1, 12, and 22 subjects were treated with an
AI in the T gel, injectable, and T pellet groups,
respectively, resulting in normalization of E levels
in all treated men. However, the clinical conse-
quences of elevated E levels in men remain poorly
understood. While an increase in E can lead to
Figure 3 Changes in hemoglobin
(Hgb) and hematocrit (Hct) during tes-
tosterone therapy (TTh). Changes in
(A) Hgb and B) Hct were assessed
over time as a function of testosterone
(T) formulation. *P < 0.05, **P < 0.001.
Table 4 Changes in Hgb and Hct after TTh initiation
Group
Baseline
mean (SD)
9 months Change
P valueMean (SD) Mean (SD)
Hgb (g/dL) 0.598
T gels 15.1 (1.1) 15.8 (1.1) 0.79 (0.9)
Injectable T 15.6 (1.3) 16.4 (1.1) 1.06 (1.4)
T pellets 14.9 (1.2) 15.7 (1.5) 0.81 (1.2)
Hct (%) 0.074
T gels 44.6 (3.1) 46.6 (3.0) 2.55 (2.6)
Injectable T 46.0 (3.7) 48.3 (2.7) 6.47 (12.4)
T pellets 44.3 (3.3) 46.5 (4.0) 2.62 (3.5)
Hct = hematocrit; Hgb = hemoglobin; SD = standard deviation; T = testosterone.
Table 5 Rates and timing of erythrocytosis as a function
of T formulation
T gels Injectable T T pellets
P valuen = 47 n = 57 n = 74
Hct >50% (n[%]) 6 (12.8) 38 (66.7) 26 (35.1) <0.0001
Time to increase
in Hct (months)
(mean [SD])
14.0 (12.6) 10.5 (9.1) 16.4 (10.7) 0.01
Hct = hematocrit; Hgb = hemoglobin; SD = standard deviation;
T = testosterone.
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gynecomastia, this is uncommon (2.2%) and is
often reversible upon discontinuation of TTh or
treatment using an AI [22–24]. Furthermore, an
increase in E levels may be beneﬁcial, as very low
E levels are associated with insulin resistance, an
increased risk of fractures, and a higher risk of
mortality in elderly men, and elevated levels of E
are associated with increased libido in men on
TTh [25–28].
One signiﬁcant concern with TTh is potential
for the development or progression of CaP, given
the androgen-responsive nature of prostate tissue.
In our cohort, we found no signiﬁcant increases in
PSA with any T formulation, irrespective of
whether treated men had a history of CaP. The
apparent lack of inﬂuence of TTh on PSA levels is
consistent with several prospective studies that
failed to demonstrate a signiﬁcant increase in PSA
[1,3,6]. However, small increases in PSA levels in
men initiating TTh during the ﬁrst few months
following therapy initiation have been observed
[29]. Furthermore, a recent study observed overall
higher PSA levels in men on T [25]. However,
these increases in PSA levels are not related to the
risk of CaP, and support the stimulation of prostate
tissue containing unsaturated androgen receptors,
as described in the prostate saturation theory pro-
posed by Morgentaler [26]. Across numerous
studies, the incidence of CaP in men on TTh is
low (1.1–2.3%), similar to the prevalence in the
general population [1,3–6,27,28,30]. In the setting
of hypogonadal men with a history of CaP treated
with TTh, no deﬁnitive data supporting a detri-
mental effect of TTh exist. In hypogonadal
men on TTh with CaP treated using radical
prostatectomy or radiation, small increases in PSA
have been observed, with no increases in CaP
recurrence rates over those seen in eugonadal men
[31–34]. Similar results have been observed in men
with CaP on active surveillance [35]. Overall,
however, these studies have been limited by their
retrospective nature and small sample sizes, pre-
cluding deﬁnitive conclusions.
Erythrocytosis is the most frequent dose-
limiting adverse effect of TTh; an increase in
blood viscosity can exacerbate preexisting vascular
disease [9]. For this study, we deﬁned
erythrocytosis as Hct ≥ 50%, which is the cutoff
value we use in clinical practice for T dose adjust-
ment or recommendation of therapeutic phle-
botomy. While all forms of TTh may lead to
increases in Hct, the rate of erythrocytosis in our
study was signiﬁcantly higher with injectable T
(66.7%) when compared with T pellets (35.1%)
and T gels (12.8%). Our ﬁndings are consistent
with a study by Dobs et al. comparing injectable
and transdermal T formulations, in which a higher
incidence of erythrocytosis (43.8%) with injectable
T relative to transdermal T (15.4%) was observed
[27]. However, the above study used an Hct cutoff
of 52% to deﬁne erythrocytosis. When adjusting
our Hct cutoff to 52%, we observe 18 (31.58%)
men on injectable T, 3 (6.38%) on T gels, and 9
(12.16%) on T pellets with erythrocytosis, similar
to the rates observed by Dobs et al. Our results are
also comparable to a recent study examining the
effects of T pellets, which observed a 20.3% rate of
erythrocytosis using a Hct cutoff of 50% [14].
Erythrocytosis also occurred signiﬁcantly earlier
in men on injectable T formulations when com-
pared with the other two formulations. While the
mechanism of T-induced erythrocytosis is unclear,
erythrocytosis is associated with supraphysiologic
T and E levels [1,2,12,27], as well as hepcidin,
dihydrotesosterone and erythropoietin levels, and
androgen receptor CAG repeat length [9,36–38]. It
should be noted that mean T levels in men treated
with injectable T were higher than those treated
with gels or pellets, which may contribute to the
increased likelihood of erythroctyosis in this group.
However, it is unclearwhether this increased rate of
erythrocytosis is related to peak T levels or overall
higher serum T levels. In our cohort, men on
injectable T had the highest increases in serum T
andE levels, whereas data were not available for the
other factors associated with erythrocytosis. Nev-
ertheless, our data support an increased risk
for erythrocytosis in men on injectable T formula-
tions. While studies directly examining the effects
of T dose on Hct are lacking, Wang et al. found a
direct relationship between T gel dose and the rate
of erythrocytosis, observing an increase in
erythrocytosis rate from 11.3% to 17.9% when
increasing T gel dose from 50 to 100 mg per day
[28]. Thus, care should be takenwhen selecting and
dosing T formulations and Hgb/Hct should be
monitored regularly.
Sex steroids play a key role in the regulation of
lipid metabolism. Activation of hepatic lipase (HL)
leads to a decrease of LDL and HDL, and
increased lipoprotein lipase (LPL) activity leads to
an increase in HDL and decreased Tchol [35].
Because TTh increases HL and LPL activity, and
further activation of LPL can result from elevated
E levels seen with TTh, TTh may have favorable
effects on lipid parameters [35]. However, studies
examining the effects of TTh on lipid proﬁles have
been variable and inconclusive, identifying both
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favorable (decreases in Tchol and LDL with inject-
able T) [39–41] and unfavorable (decreases in
HDL and increases in Tchol and LDL with inject-
able and pellet T) [42,43] effects on lipid param-
eters. A recent meta-analysis examining 51 studies
using various T formulations (28 injectable T, 17
transdermal T, and 6 oral T) found that the only
change in lipids during TTh was a small, but sig-
niﬁcant decrease in HDL [10]. We did not observe
an effect on HDL in our cohort and no consistent,
signiﬁcant changes in any lipid parameter were
observed. This may be due to the fact that the lipid
levels in our cohort were not consistently drawn
from fasting patients, as they had been in the pre-
vious study observing a decrease in Tchol and
LDL levels with TTh [35]. Furthermore, changes
in the diets of subjects in our study were not
tracked, so the inﬂuence of diet on lipid param-
eters in our cohort cannot be determined.
The strengths of this study include the selection
ofT-naïvemenormenwhohadbeenoff ofTTh for
3 or more months, that all men in the study were
treated using a single T formulation for the dura-
tion of follow-up, the study’s single-center design,
the long follow-up period, and the reproducibility
associated with utilizing a single laboratory for
evaluation of all serum variables. Furthermore, the
ability to compare T formulations within a single
clinic setting is signiﬁcant. Our study is limited by
several factors, including its retrospective design,
precluding the ability to randomize the cohort to
treatment and limiting the ability to evaluate the
impact of confounding factors, the lack of fasting
lipid parameters in all patients, the use of AIs, and
the relatively small sample size necessitated by the
rigorous patient selection schema. Furthermore,
the 3 T formulation groups are imperfectly
matched, with differing ages and comorbidities
between groups, as well as varying levels of T and
FT observed during follow-up, limiting the ability
to compare the groups.
In summary, this study supports prior ﬁndings
associating different T formulations with variable
adverse effect rates. Speciﬁcally, injectable T for-
mulations are associated with signiﬁcant increases
in E and higher erythrocytosis rates relative to T
gels and pellets, possibly related to elevated mean
or peak T levels. PSA levels are not affected by T
formulation, and inconsistent variations in lipid
levels occur, also apparently independently of T
formulation. Understanding the differences in
effect proﬁles for each T formulation is useful for
individualizing TTh and identifying parameters
that require regular monitoring.
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version of this article at the publisher’s website:
Figure S1 Changes in lipid parameters during TTh.
Changes in (A) total cholesterol, (B) Triglycerides, (C) LDL Cho-
lesterol, and (D) HDL Cholesterol were assessed over time as a
function of T formulation.
Table S1 Summary serum data during follow-up.
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